Phospholipids constitute a catalytic surface for the enzymatic activation of coagulation factors. Lupus circulating anticoagulants are heterogeneous autoantibodies of the IgG and IgM type directly directed against a variety of anionic phospholipids such as cardiolipin, phosphatidylserine or phosphatidylinositol or against proteins having the capacity to bind to phospholipids such as β2-glycoprotein I (β2 -GPI).
The contribution of phospholipids (PL) does not modify the levels of factors VIII, IX, XI, XII on normal plasmas without deficit nor LA. The contribution of PL does not modify the levels of factors VIII, IX, XI, XII on the known deficient plasmas with and without LA (isolated constitutional or acquired deficiency).
The supply of PL leads to an increase in factors VIII, IX, XI, XII in plasmas with LA.
This solution has a strong procoagulant activity. It can be used in general hemostasis research and more particularly in the test for the thrombin generation methods with or without activated protein C.
Expiration date of 30 months from the date of manufacture with storage at 2 °C / 8 °C.
This PL concentrate provides a possible alternative in the event of persistent difficulties due to LA on the assay of factors VIII, IX, XI or other hemostasis tests disturbed by the presence of LA.
Phospholipid-TGT constitutes a well defined emulsion containing synthetic phosphatidyl serine, phosphatidyl choline and highly purified sphingomyelin from egg yolk.
Phospholipid-TGT has rapidly demonstrated its utility in hemostasis assays involving phospholipids.
